| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/NAR/20.17.4581 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC334188 |
| https://europepmc.org/articles/PMC334188?pdf=render | ||
| P932 | PMC publication ID | 334188 |
| P698 | PubMed publication ID | 1408760 |
| P5875 | ResearchGate publication ID | 21746475 |
| P2093 | author name string | C. J. Chen | |
| G. G. Harmison | |||
| M. Schubert | |||
| K. Haglund | |||
| A. C. Banerjea | |||
| P2860 | cites work | The accuracy of reverse transcriptase from HIV-1. | Q54738770 |
| Fidelity of HIV-1 reverse transcriptase | Q56904813 | ||
| A small catalytic oligoribonucleotide | Q59060304 | ||
| Making Sense of Antisense | Q67923149 | ||
| In vitro cleavage of HIV-1 vif RNA by a synthetic ribozyme | Q70140348 | ||
| Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase | Q26778389 | ||
| Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites | Q28304694 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Rapid evolution of RNA genomes | Q29616272 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| Location of the binding domains for the RNA polymerase L and the ribonucleocapsid template within different halves of the NS phosphoprotein of vesicular stomatitis virus | Q30450897 | ||
| Primary structure of the vesicular stomatitis virus polymerase (L) gene: evidence for a high frequency of mutations | Q30452272 | ||
| The chemistry of self-splicing RNA and RNA enzymes | Q30457285 | ||
| The human immunodeficiency virus: infectivity and mechanisms of pathogenesis | Q34049376 | ||
| Replication and pathogenesis of the AIDS virus. | Q34164817 | ||
| Specific gene suppression by engineered ribozymes in monkey cells | Q34321871 | ||
| A human beta-actin expression vector system directs high-level accumulation of antisense transcripts | Q34638492 | ||
| Insertion of the human immunodeficiency virus CD4 receptor into the envelope of vesicular stomatitis virus particles | Q36692234 | ||
| Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. | Q36798367 | ||
| Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. | Q36831564 | ||
| Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes | Q36843702 | ||
| Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme | Q37581969 | ||
| Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein | Q37631307 | ||
| Ribozyme mediated destruction of RNA in vivo | Q40822323 | ||
| Simple RNA enzymes with new and highly specific endoribonuclease activities | Q43501578 | ||
| Ribozymes that cleave an RNA sequence from human immunodeficiency virus: the effect of flanking sequence on rate | Q45853290 | ||
| Gene therapy. Intracellular immunization | Q45887946 | ||
| Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. | Q50804065 | ||
| Cell lines that express stably env gene products from three strains of HIV-1. | Q52831221 | ||
| Ribozymes as potential anti-HIV-1 therapeutic agents. | Q54719925 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribozyme | Q205858 |
| P304 | page(s) | 4581-4589 | |
| P577 | publication date | 1992-09-01 | |
| 1992-09-11 | |||
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates | |
| P478 | volume | 20 |
| Q37311199 | A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread |
| Q34982905 | A method to increase the cumulative cleavage efficiency of ribozymes: thermal cycling |
| Q34442731 | A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. |
| Q40396975 | Activation and inactivation of gene expression using RNA sequences |
| Q41528506 | Anti-HIV ribozymes |
| Q41563534 | Anti-gene therapy: the use of ribozymes to inhibit gene function |
| Q41526877 | Anti-oncogene Ribozymes for Cancer Gene Therapy |
| Q38297215 | Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects |
| Q40923006 | Antisense and ribozyme constructs in transgenic animals |
| Q37328072 | Antisense makes sense in engineered regenerative medicine |
| Q41609445 | Antiviral ribozymes. New jobs for ancient molecules |
| Q40224978 | Can hammerhead ribozymes be efficient tools to inactivate gene function? |
| Q38316752 | Cleavage of full-length beta APP mRNA by hammerhead ribozymes |
| Q40403807 | Controlled, targeted, intracellular expression of ribozymes: progress and problems |
| Q34452681 | Delivery of novel macromolecular drugs against HIV-1. |
| Q35020155 | Design and specificity of hammerhead ribozymes against calretinin mRNA. |
| Q36607437 | Design requirements for interfering particles to maintain coadaptive stability with HIV-1. |
| Q45883446 | Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer |
| Q40539253 | Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites |
| Q39089057 | First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene |
| Q33597455 | Function and biological applications of catalytic nucleic acids |
| Q30370880 | Gene silencing: a therapeutic approach to combat influenza virus infections. |
| Q41262158 | Gene therapeutic approaches to primary and metastatic brain tumors: II. ribozyme-mediated suppression of CD44 expression |
| Q34208320 | Gene therapy for HIV. |
| Q33992464 | Gene therapy for infectious diseases |
| Q34837666 | Hammerhead ribozymes for target validation |
| Q36700451 | Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus |
| Q35824479 | Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene |
| Q40451946 | Inhibition of gene expression with ribozymes. |
| Q40828317 | Inhibition of hepatitis B virus X gene expression by novel DNA enzymes |
| Q41707158 | Intracellular expression and function of antisense catalytic RNAs |
| Q36494676 | Molecular determinants of the ratio of inert to infectious virus particles |
| Q53871590 | Multitarget ribozyme against the S1 genome segment of reovirus possesses novel cleavage activities and is more efficacious than its constituent mono-ribozymes. |
| Q40795813 | Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression |
| Q39509279 | Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site. |
| Q39542351 | RNA double cleavage by a hairpin-derived twin ribozyme. |
| Q34459382 | RNA-based gene therapy for HIV infection |
| Q40228623 | Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme |
| Q74474267 | Regulation of CAT protein by ribozyme and antisense mRNA in transgenic mice |
| Q40756505 | Regulation of human immunodeficiency virus infection: implications for pathogenesis |
| Q40445903 | Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. |
| Q34062644 | Ribozyme therapy for HIV infection |
| Q35808611 | Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines |
| Q33751872 | Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. |
| Q35055493 | Ribozymes that cleave reovirus genome segment S1 also protect cells from pathogenesis caused by reovirus infection |
| Q40456051 | Ribozymes: biology, biochemistry, and implications for clinical medicine. |
| Q35107854 | Ribozymes: recent advances in the development of RNA tools |
| Q41337500 | Ribozymes: structure, function, and potential therapy for dominant genetic disorders |
| Q39026369 | Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme |
| Q39234855 | Strategies for the suppression of peroxidase gene expression in tobacco. I. Designing efficient ribozymes. |
| Q77135127 | Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion |
| Q45722208 | Targeted cleavage of hepatitis E virus 3' end RNA mediated by hammerhead ribozymes inhibits viral RNA replication |
| Q40393204 | Therapy Other Than Reverse Transcriptase Inhibitors for HIV Infection |
| Q43692686 | Transcripts containing a small anti-HIV hammerhead ribozyme that are active in the cell cytoplasm but inactive in vitro as free RNAs |
Search more.